From the Neuroepidemiology Research Unit (C.W., D.E.G.), Research Institute of the McGill University Health Centre; Department of Medicine (C.W.), Faculty of Medicine and Health Sciences, Department of Epidemiology (C.W., F.I.), Biostatistics and Occupational Health, School of Population and Global Health, and Department of Pediatrics (M.O.), Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
Neurology. 2023 Aug 8;101(6):e613-e623. doi: 10.1212/WNL.0000000000207474. Epub 2023 Jun 12.
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disorder affecting upper and lower motor neurons. Due to its rarity and rapidly progressive nature, studying the epidemiology of ALS is challenging, and a comprehensive picture of the global burden of this disease is lacking. The objective of this systematic review was to describe the global incidence and prevalence of ALS.
We searched MEDLINE, Embase, Global Health, PsycInfo, Cochrane Library, and CINAHL to identify articles published between January 1, 2010, and May 6, 2021. Studies that were population based and reported estimates of prevalence, incidence, and/or mortality of ALS were eligible for inclusion. This study focuses on the incidence and prevalence. Quality assessment was performed using a tool developed to evaluate methodology relevant to prevalence and incidence studies. This review was registered with PROSPERO, CRD42021250559.
This search generated 6,238 articles, of which 140 were selected for data extraction and quality assessment. Of these, 85 articles reported on the incidence and 61 on the prevalence of ALS. Incidence ranged from 0.26 per 100,000 person-years in Ecuador to 23.46 per 100,000 person-years in Japan. Point prevalence ranged from 1.57 per 100,000 in Iran to 11.80 per 100,000 in the United States. Many articles identified cases with ALS from multiple data sources.
There is variation in reported incidence and prevalence estimates of ALS across the world. While registries are an important and powerful tool to quantify disease burden, such resources are not available everywhere. This results in gaps in reporting of the global epidemiology of ALS, as highlighted by the degree of variation (and quality) in estimates of incidence and prevalence reported in this review.
肌萎缩侧索硬化症(ALS)是一种罕见的神经退行性疾病,影响上下运动神经元。由于其罕见性和快速进展的性质,研究 ALS 的流行病学具有挑战性,并且缺乏对这种疾病全球负担的全面了解。本系统评价的目的是描述 ALS 的全球发病率和患病率。
我们检索了 MEDLINE、Embase、全球健康、PsycInfo、Cochrane 图书馆和 CINAHL,以确定 2010 年 1 月 1 日至 2021 年 5 月 6 日期间发表的文章。符合条件的研究是基于人群的,并报告了 ALS 的患病率、发病率和/或死亡率的估计值。本研究重点关注发病率和患病率。使用评估与患病率和发病率研究相关的方法的工具进行质量评估。本综述在 PROSPERO 中进行了注册,CRD42021250559。
该搜索共生成了 6238 篇文章,其中 140 篇被选作数据提取和质量评估。其中,85 篇文章报告了 ALS 的发病率,61 篇报告了 ALS 的患病率。发病率从厄瓜多尔的每 100000 人年 0.26 例到日本的每 100000 人年 23.46 例不等。时点患病率从伊朗的每 100000 人 1.57 例到美国的每 100000 人 11.80 例不等。许多文章从多个数据源中确定了 ALS 病例。
全球 ALS 的发病率和患病率估计值存在差异。虽然登记册是量化疾病负担的重要且强大的工具,但并非在所有地方都有此类资源。这导致了 ALS 全球流行病学报告的空白,正如本综述中报告的发病率和患病率估计值的差异(和质量)所突出的那样。